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Introduction. The main features of metabolic syndrome are obesity, insulin 
resistance, disorders of carbohydrate and lipid metabolism and arterial hypertension 
[1]. According to modern data, about 1.4 million people in the world are obese [4]. 
In developed countries, obesity is diagnosed in 27% of adults and in more than 
15% of adolescents. However, its frequency is steadily increasing [1, 2]. Central 
obesity in combination with insulin resistance leads to the development of arterial 
hypertension, cardiovascular diseases, violation of carbohydrate metabolism, which 
are components of the metabolic syndrome (MS) [3]. Above all insulin resistance 
plays the most important role in the development of metabolic syndrome [2]. The 
main target of tactics in metabolic syndrome must be pathogenesis treatment [5]. 
Aim. The influence of metformin on insulin resistance indexes in children 
and adolescence with metabolic syndrome was the subject of the research.  
Materials and methods. 96 children and adolescence with metabolic 
syndrome were observed. The diagnosis of metabolic syndrome was made on the 
base of obesity, arterial hypertension, disorders of carbohydrate and lipid 
metabolism according to the АТР III (2001) и IDF (2005) recommendations. C-
peptide was determined using the immunoferment method. Insulin resistance index 
HOMA-IR was calculated using the formula HOMA-IR=G (serum glucose level 
(mmol/L) х Ins (serum immune reactive insulin) (mcUnits/mL) : 22,5; normal – 
less than 3,5.  
Statistic analysis was made using the program Statistika (ver 2009 for 
Windows), criteria Mann-Whitney, Wilkinson and χ². 
Results and discussion.  
All patients were randomized into 2 groups: first group: 48 children and 
adolescence received diet and physical training; second group (48 children and 
adolescence) received diet, physical training and metformin.  
The proposed course of therapy lasted for 6 months and the dose of 
metformin was 1500 – 2000 mg daily.  
The comparing of insulin resistance indexes established that after 3 month in 
children of the 1 group serum C-peptide decreased from 4,2±1,05 ng/ml till 
4,15±1,01 ng/ml, and at 2
nd
 group (with metformin) this index decreased from 
4,22±1,05 ng/ml till 3,18±0,96 ng/ml (р=0,045).  
Insulin resistance index in the 1 group decreased from 5,06±1,16 till 
5,01±1,11, and in the 2
nd
 group from  5,05±1,15 till 4,17±1,01 (р=0,007). 
After 6 months the rate of С-peptide in the 1 group became 4,01±0,98 ng/ml, 
and in the 2
nd
 group this index decreased to 2,79±0,51 ng/ml (р<0,001). Insulin 
resistance index in the 1 group became 4,83±1,01, and in the 2
nd
 group it decreased  
to 3,01±0,71 (р<0,001).  
It should be noted that our data was confirmed that no side effects of 
metformin in children were established. 
Conclusions.  
1. Our data confirmed a statistically significant reduction in the level of 
insulin resistance under the influence of treatment with metformin.  
2. Metformin treatment was well tolerated and can be regarded as a 
pathogenesis factor in the treatment of metabolic syndrome in children. 
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